D. Ginard , I. Marín-Jiménez , M. Barreiro de Acosta , E. Ricart , E. Domènech , J.P. Gisbert , M. Esteve , M. Mínguez , en representación de GETECCU
{"title":"Recomendaciones sobre el uso e indicaciones del tratamiento tópico en pacientes con colitis ulcerosa","authors":"D. Ginard , I. Marín-Jiménez , M. Barreiro de Acosta , E. Ricart , E. Domènech , J.P. Gisbert , M. Esteve , M. Mínguez , en representación de GETECCU","doi":"10.1016/j.eii.2015.06.002","DOIUrl":null,"url":null,"abstract":"<div><p>Although most patients with ulcerative colitis should be treated with topical treatment, different studies have shown that they are underused. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of the available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission is evaluated. Finally, some recommendations are given to better inform patients about the proper implementation and administration of topical treatment.</p></div>","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"14 2","pages":"Pages 41-47"},"PeriodicalIF":0.0000,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.06.002","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedad Inflamatoria Intestinal al Día","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S169678011500041X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Although most patients with ulcerative colitis should be treated with topical treatment, different studies have shown that they are underused. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of the available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission is evaluated. Finally, some recommendations are given to better inform patients about the proper implementation and administration of topical treatment.